BB...I believe that the judge Du decision on March 30 made the heads of Amarim management spin in the days and weeks after March 30 and discouraged them from initiating a more pro-active campaign to study Vascepa for COVID-19 virus...potentially it can yield at least some anti-inflammatory help to those patients afflicted with early stage COVID-19 infections...just as it provided anti-inflammatory protection against cardiovascular diseases....I am glad that studies are now belatedly getting underway in Canada.